Performance of Pressurized Metered‐Dose Inhalers at Extreme Temperature Conditions. Issue 11 (22nd September 2014)

• Record Type: Journal Article
• Authors: Morin, Chelsea M. D.; Ivey, James W.; Titosky, Jordan T. F.; Suderman, Jonathan D.; Olfert, Jason S.; Vehring, Reinhard; Finlay, Warren H.
• Is Part Of: Journal of pharmaceutical sciences. Volume 103:Issue 11(2014:Nov.)
• Page Start: 3553
• Page End: 3559
• Publication Date: 2014-09-22
• Subjects: Pharmacy -- Periodicals; 615.1
• DOI: 10.1002/jps.24145
• Languages: English
• ISSNs: 0022-3549

Abstract

<abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <p>The performance of pressurized metered‐dose inhalers (pMDIs) under a variety of temperature conditions was investigated. The effects of both inhaler temperature and ambient temperature were considered. The inhaler temperature ranged from −13.0°C to 41.7°C and the ambient temperature ranged from −12.0°C to 41.7°C. The <italic>in vitro</italic> lung dose was measured for four widely available pMDIs: Airomir^TM, QVAR^TM, Symbicort^®, and Ventolin^®. The <italic>in vitro</italic> lung dose through an Alberta Idealized Throat was measured by gravimetric assay, which was verified by UV spectroscopic assay. A decrease in the <italic>in vitro</italic> lung dose was observed for all evaluated pMDIs when ambient temperature and device temperature were simultaneously reduced, decreasing on average by 70% at the coldest temperatures, whereas increasing on average by 25% at the elevated temperature condition. <italic>In vitro</italic> lung dose is strongly dependent on both inhaler temperature and ambient temperature with the tested pMDIs. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:3553–3559, 2014</p> </abstract>